Premium
Histopathological characteristics of microfocal prostate cancer detected during systematic prostate biopsy
Author(s) -
Guttilla Andrea,
Zazzara Michele,
Zattoni Fabio,
Novara Giacomo,
Zanin Martina,
Gardiman Marina,
Ficarra Vincenzo,
Zattoni Filiberto
Publication year - 2015
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12786
Subject(s) - medicine , prostate cancer , interquartile range , biopsy , prostate , prostatectomy , prostate biopsy , pathological , prostate specific antigen , urology , receiver operating characteristic , retrospective cohort study , cancer , radiology
Objective To evaluate the prevalence of adverse pathological features and the percentage of multifocal and/or bilateral disease in a series of patients who underwent radical prostatectomy ( RP ) for unique, microfocal prostate cancer (mi PC a) detected on prostate biopsy in the pre‐active surveillance ( AS ) era. Patients and Methods In this retrospective, multi‐institutional study, we analysed the clinical records of 131 consecutive patients who underwent either retropubic or robot‐assisted RP for mi PC a at two referral centres from January 2000 to December 2011. mi PC a was defined as a neoplastic lesion present in ≤10% of core with biopsy Gleason score not applicable or biopsy Gleason score 6. Results There were 17 (13%) pT 3–4 prostate cancers and a single case (0.8%) of pN + tumour. Moreover, 31 (24.1%) patients had a Gleason score of >6 in the RP specimen. Therefore, unfavourable pathological features ( pT 3–4/N+ and/or Gleason score >6) were present in 40 (30.5%) patients. The median (interquartile range) prostate‐specific antigen ( PSA ) density was 0.11 (0.09–0.17) and 0.16 (0.11–0.24) ng/mL/mL in patients with favourable and unfavourable pathological characteristics, respectively ( P = 0.003). The receiver operating characteristic curve had an area under the curve value of 0.67 (95% confidence interval 0.56–0.77) for PSA density to predict the risk of unfavourable pathological features. Conclusion Patients with mi PC a who are candidates for an AS protocol should be adequately informed that in ≈30% of cases the cancer might be locally advanced and/or with a Gleason score of >6. Those unfavourable pathological characteristics could be predicted by the PSA density value. Further studies should investigate the role of a more extensive biopsy sampling to reduce the risk of under‐staging and/or under‐grading in patients with an initial diagnosis of mi PC a.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom